001     136803
005     20240229105100.0
024 7 _ |a 10.1007/s11136-018-1866-8
|2 doi
024 7 _ |a pmid:29740782
|2 pmid
024 7 _ |a 0962-9343
|2 ISSN
024 7 _ |a 1573-2649
|2 ISSN
024 7 _ |a altmetric:40869146
|2 altmetric
037 _ _ |a DKFZ-2018-01241
041 _ _ |a eng
082 _ _ |a 100
100 1 _ |a Schmidt, Martina
|0 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
|b 0
|e First author
245 _ _ |a Quality of life, problems, and needs of disease-free breast cancer survivors 5 years after diagnosis.
260 _ _ |a Dordrecht [u.a.]
|c 2018
|b Springer Science + Business Media B.V
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1539690417_27975
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a After cancer treatment, it is desirable to maintain or regain a high quality of life (QoL) and the ability to accomplish everyday tasks well. Therefore, we substantiated the scarce knowledge regarding long-term QoL after breast cancer, burdensome problems, and unmet needs for more support.Disease-free breast cancer survivors (n = 190) who had participated in two randomized controlled exercise trials during primary treatment were followed up to 5 years post-diagnosis. QoL-related functions and symptoms (EORTC QLQ-C30/-BR23), health problems, and support needs were assessed. EORTC-QLQ scores were compared with age-matched normative values from the general population in Germany.QoL-related functions and symptoms in patients during cancer treatment were worse compared to healthy references, but largely improved over time. Yet, cognitive function and sleep were still significantly impaired at 5-year follow-up. Other common long-term problems included sexual issues (45% of survivors), hot flashes (38%), pain (34%), fatigue (24%), and polyneuropathy (21%). Regression analyses indicated fatigue having the strongest impact on global QoL. Support needs were expressed mainly for menopausal disorders (43%), physical performance (39%), sleep problems (38%), arthralgia (37%), cognitive problems (36%), weight problems (32%), and fatigue (31%).While QoL in disease-free breast cancer survivors 5 years post-diagnosis was largely comparable to the general population on average, still many survivors suffered from adverse effects. There appears to be a need for ongoing screening and support regarding fatigue, sleep problems, cognitive problems, arthralgia/pain, menopausal/sexual symptoms, physical performance, and weight problems during and several years following breast cancer therapy.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Wiskemann, Joachim
|0 P:(DE-He78)60b584aeef81e4c57fd111fa63779b73
|b 1
700 1 _ |a Steindorf, Karen
|0 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
|b 2
|e Last author
773 _ _ |a 10.1007/s11136-018-1866-8
|g Vol. 27, no. 8, p. 2077 - 2086
|0 PERI:(DE-600)2008960-0
|n 8
|p 2077 - 2086
|t Quality of life research
|v 27
|y 2018
|x 1573-2649
909 C O |p VDB
|o oai:inrepo02.dkfz.de:136803
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-He78)60b584aeef81e4c57fd111fa63779b73
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)a0c2037d9054be26907a05ae520d5756
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a National-Konsortium
|0 StatID:(DE-HGF)0430
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b QUAL LIFE RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0130
|2 StatID
|b Social Sciences Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1180
|2 StatID
|b Current Contents - Social and Behavioral Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
920 1 _ |0 I:(DE-He78)G210-20160331
|k G210
|l Bewegung, Präventionsforschung und Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G210-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21